Akums Drugs and Pharmaceuticals Ltd (NSE:AKUMS)

Q1 2027 Akums Drugs and Pharmaceuticals Ltd Earnings Call Transcript

Aug 10, 2026 / 06:30 AM GMT

Release Date Price: ₹730.1 (+4.68%)

Transcript

Key Points

Positve

Akums Drugs and Pharmaceuticals Ltd (BOM:544222) reported a strong Q1 FY27 with revenue growth of 13.9% YoY and a 35.4% increase in EBITDA, driven by the CDMO segment's double-digit volume growth and improved API prices.
The CDMO segment delivered a robust 18.6% YoY revenue growth, with management confident of continued high-teens volume growth in Q2 and a full-year EBITDA margin guidance of 14-15%, potentially trending to the upper end.
The company's balance sheet remains exceptionally healthy with a net cash surplus of Rs 1,616 crores, providing ample firepower for strategic acquisitions and future growth initiatives.
The acquisition of Oriflame India's manufacturing business expands Akums Drugs and Pharmaceuticals Ltd (BOM:544222)'s footprint into high-margin skincare, cosmetics, and wellness products, aligning with its strategy to tap niche formulations.
The API segment is showing clear progress toward profitability, with losses narrowing to Rs 4 crore from Rs 6 crore YoY, driven by a higher share of non-SEVA products, and management targets monthly EBITDA positivity by end of FY27.
The domestic branded formulation business (Acumentis) resumed growth with a 7.3% YoY revenue increase, supported by a 15% expansion in field force, which is expected to drive improved performance from Q3 onwards.

Negative

The domestic branded formulation segment's EBITDA declined 25.4% YoY due to the cost of hiring nearly 200 new field staff, which will continue to pressure margins in the near term.
The international branded formulation business saw a muted quarter with revenue declining 1.5% YoY and EBITDA falling 14.4%, with no clear timeline for a return to growth.
The API segment continues to report losses, with revenue declining 29.7% YoY to Rs 32 crore, and management has not provided a definitive timeline for achieving full-year profitability.
The trade generic segment experienced a 9.5% YoY revenue decline and a 23.4% QoQ drop, with EBITDA only at breakeven, indicating ongoing weakness in this business.
Management's guidance for the Zambia order (expected in H2) and the European business (starting next fiscal year) remains uncertain, with no concrete revenue or margin figures provided beyond broad expectations.
The company's strategy of maintaining significant spare capacity (currently at ~50% utilization) may limit near-term margin expansion, as it continues to invest in new facilities like the Baddi plant without clear returns.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AKUM.NS - Akums Drugs and Pharmaceuticals Ltd
Q1 2027 Akums Drugs and Pharmaceuticals Ltd Earnings Call
Aug 10, 2026 / 06:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, ladies and gentlemen. Welcome to the Ekam Drugs and Pharmaceuticals Q1 FY27 earnings conference call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference call, please signal an operator by pressing *, then 0 on your touchstone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Umesh Latta.

Thank you, and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.